Last reviewed · How we verify
APG777
APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.
APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3. Used for Solid tumors with FGFR alterations.
At a glance
| Generic name | APG777 |
|---|---|
| Sponsor | Apogee Therapeutics, Inc. |
| Drug class | multikinase inhibitor |
| Target | FGFR1, FGFR2, FGFR3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
APG777 works by selectively inhibiting the activity of fibroblast growth factor receptors 1, 2, and 3, which are involved in the regulation of cell growth and division. This inhibition can lead to the reduction of tumor growth and metastasis. APG777 has shown promise in preclinical studies as a potential treatment for various types of cancer.
Approved indications
- Solid tumors with FGFR alterations
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis (PHASE2)
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma (PHASE1)
- A Study Evaluating APG777 in Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APG777 CI brief — competitive landscape report
- APG777 updates RSS · CI watch RSS
- Apogee Therapeutics, Inc. portfolio CI